In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Onyx Pharmaceuticals, Inc.

http://www.onyx-pharm.com

Latest From Onyx Pharmaceuticals, Inc.

Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?

Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.

South Korea Financing

Are Korean Biopharma Alliances Recovering After Gloomy Year?

Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.

South Korea Deals

How Roche Plans To Stay Ahead In MS And Catch Up In Alzheimer’s

Neuroscience is increasingly a focus for the Swiss pharma giant, and it believes it can stay ahead in multiple sclerosis with fenebrutinib, while making up lost ground in with two key candidates in Alzheimer’s disease.

Companies Neurology

Breakdowns In The Breakthrough Lane: When Recipients Of FDA Expedited Designation Fall Short

Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.

US FDA Performance Tracker Drug Review
See All

Company Information

  • Other Names / Subsidiaries
    • Proteolix, Inc.
UsernamePublicRestriction

Register